-+ 0.00%
-+ 0.00%
-+ 0.00%

BENITEC BIOPHARMA ANNOUNCES ACCEPTANCE OF LATE- BREAKING ABSTRACT FOR THE BB-301 PHASE 1B/2A CLINICAL TREATMENT STUDY AT THE MUSCULAR DYSTROPHY ASSOCIATION CLINICAL & SCIENTIFIC CONFERENCE

Reuters·02/23/2026 12:00:02

Please log in to view news